Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption

被引：24
|
作者：
Laroni, A. [1 ]
Brogi, D. [1 ]
Milesi, V. [1 ]
Abate, L. [1 ]
Uccelli, A. [1 ]
Mancardi, G. L. [1 ]
机构：
[1] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, I-16132 Genoa, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2013年 / 19卷 / 09期
关键词：
MULTIPLE-SCLEROSIS;
D O I：
10.1177/1352458512468498
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：1236 / 1237
页数：2
相关论文
共 50 条
  • [11] Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients
    Leurs, Cyra E.
    van Kempen, Zoe L. E.
    Dekker, Iris
    Balk, Lisanne J.
    Wattjes, Mike P.
    Rispens, Theo
    Uitdehaag, Bernard M. J.
    Killestein, Joep
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (11) : 1453 - 1460
  • [12] Efficacy and safety of alemtuzumab versus fingolimod in RRMS patients after switch from natalizumab: a retrospective analysis
    Pfeuffer, S.
    Ruck, T.
    Kleinschnitz, C.
    Wieshuber, M.
    Lee, D-H.
    Linker, R.
    Doerck, S.
    Straeten, V.
    Windhagen, S.
    Aufenberg, C.
    Lang, M.
    Christian, E.
    Tackenberg, B.
    Wiendl, H.
    Meuth, S. G.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 334 - 335
  • [13] Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity
    Spelman, Tim
    Horakova, Dana
    Ozakbas, Serkan
    Alroughani, Raed
    Onofrj, Marco
    Kalincik, Tomas
    Prat, Alexandre
    Terzi, Murat
    Grammond, Pierre
    Patti, Francesco
    Csepany, Tunde
    Boz, Cavit
    Lechner-Scott, Jeannette
    Granella, Franco
    Grand'Maison, Francois
    van der Walt, Anneke
    Zhu, Chao
    Butzkueven, Helmut
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 70
  • [14] Incidence of recurrence of disease activity after fingolimod discontinuation in older patients
    Pantazou, V.
    Pot, C.
    Le Goff, G.
    Du Pasquier, R.
    Theaudin, M.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 162 - 163
  • [15] Risk of cardiovascular disease in patients treated with fingolimod compared to natalizumab: A nationwide cohort study in Denmark
    Framke, Elisabeth
    Thygesen, Lau Caspar
    Malmborg, Morten
    Schou, Morten
    Sellebjerg, Finn
    Magyari, Melinda
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 368 - 368
  • [16] Decrease of Treg lymphocytes count is associated with relapse risk after natalizumab withdrawal
    Labeyrie, C.
    Papeix, C.
    Maillart, E.
    Louapre, C.
    Theaudin, M.
    Arnaud, L.
    Stankoff, B.
    Corvol, J. C.
    Gorochov, G.
    Lubetzki, C.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 384 - 384
  • [17] Short term disease activity after switching from natalizumab to fingolimod does not predict long term fingolimod efficacy a retrospective study
    Coclitu, C.
    Riggi, F.
    Vaillant, M.
    Casez, O.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 341 - 341
  • [18] Multiple sclerosis disease rebound after treatment switch from fingolimod to alemtuzumab
    Willis, M.
    Pearson, O.
    Illes, Z.
    Nielsen, C.
    Sejbaek, T.
    Duddy, M.
    Petheram, K.
    van Munster, C.
    Killestein, J.
    Uitdehaag, B.
    Malmestrom, C.
    Tallantyre, E.
    Robertson, N.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 664 - 665
  • [19] Independent Risk Factors of Early Recurrence After Curative Resection for Perihilar Cholangiocarcinoma: Adjuvant Chemotherapy May Be Beneficial in Early Recurrence Subgroup
    Zhao, Jian
    Zhang, Wei
    Zhang, Jun
    Chen, Yun-Tian
    Ma, Wen-Jie
    Liu, Si-Yun
    Li, Fu-Yu
    Song, Bin
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 13111 - 13123
  • [20] Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis
    Meinl, Ingrid
    Havla, Joachim
    Hohlfeld, Reinhard
    Kuempfel, Tania
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (07) : 991 - 994
12345